Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

Next Previous
Trial Profile

Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evacetrapib (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCELERATE
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 27 Jul 2020 This trial is completed in UK (Global End Date: 12 Oct 2015), according to European Clinical Trials Database record.
    • 30 Mar 2020 Results (N=8758), post-hoc analysis assessing the clinical effects of Evacetrapib in patients with high risk for vascular outcomes, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
    • 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top